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Introduction
In the medical treatment, of acute cholangitis, antimi-
crobial agents should be chosen empirically and care-
fully. As soon as a diagnosis of acute cholangitis is 
considered, antimicrobial agents should be selected em-
pirically, with careful consideration of several factors, 
including antimicrobial activity against the causative 
bacteria, the severity of the cholangitis, the presence/
absence of renal and hepatic disease, a recent (1-year) 
history of antimicrobial therapy, local susceptibility pat-
terns (antibiogram), and (although controversies still 
exist) the biliary penetration of the antimicrobial agents. 
Whenever any presumptive or empirical antimicrobial 
agents are used, they should be switched for the best 
available narrower-spectrum agents to avoid superin-
fection or the emergence of antimicrobial resistance as 
a cause of treatment failure. Long-term administration 
without an acceptable rationale should be avoided. In 
this article, we review previous bacteriological studies 
and clinical trials. We also provide current recommen-
dations for the antimicrobial agents to be used for acute 
cholangitis, in an evidence- and consensus-based man-
ner, on the basis of discussions at the Tokyo Interna-
tional Consensus Meeting.
Abstract
Antimicrobial agents should be administered to all patients 
with suspected acute cholangitis as a priority as soon as pos-
sible. Bile cultures should be performed at the earliest op-
portunity. The important factors which should be considered 
in selecting antimicrobial therapy include the agent’s activity 
against potentially infecting bacteria, the severity of the chol-
angitis, the presence or absence of renal and hepatic diseases, 
the patient’s recent history of antimicrobial therapy, and any 
recent culture results, if available. Biliary penetration of the 
microbial agents should also be considered in the selection of 
antimicrobials, but activity against the infecting isolates is of 
greatest importance. If the causative organisms are identifi ed, 
empirically chosen antimicrobial drugs should be replaced by 
narrower-spectrum antimicrobial agents, the most appropri-
ate for the species and the site of the infection.
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Q1. How to detect causative organisms of acute 
cholangitis?
Bile/blood culture should be performed at all 
available opportunities (recommendation B).
Table 1 lists the positive rates of bacterial cultures in 
bile in various biliary diseases. While bile is sterile in 
individuals without any biliary disease, a positive bile 
culture is common in various biliary diseases. In pa-
tients with acute cholangitis and choledocholithiasis, 
a positive bile culture is correlated with progression 
to severe cholangitis and a high mortality rate (level 
2b-3b).1,2 Also, care should be exercised regarding the 
postoperative occurrence of infective complications in 
patients with positive bile cultures (level 5).3 These 
facts emphasize the importance of early antimicrobial 
therapy.
It was reported that microbial organisms contained in 
bile from various biliary diseases were of intestinal bac-
terial fl ora origin (Table 2). Aerobic bacteria such as 
Escherichia coli, Klebsiella, Enterococcus, and Entero-
bacter are most frequently isolated, whereas Streptococ-
cus spp., Pseudomonas, and Proteus are less frequently 
isolated (level 2b-3b).2,4–8 Although anaerobic bacteria 
such as Clostridium and Bacteroides are often isolated, 
most of these patients have polymicrobial infections 
with aerobic bacteria (level 5).9–11 There are reports that 
anaerobic bacteria are often detected patients with se-
vere acute cholangitis (level 2b-3b).12–14
Moreover, it should also be kept in mind for the 
 estimation of causative bacteria in acute cholangitis, 
whether the infection is community-acquired or hospi-
tal-acquired. When it is community-acquired, intestinal 
microorganisms such as E. coli, Klebsiella, and Entero-
coccus are likely to be the causative bacteria. By con-
trast, we have to take into account that, in patients with 
hospital-acquired type infections, especially those in a 
postoperative state or those with indwelling stents and 
malignancies, more resistant organisms, i.e., methicillin-
resistant Staphylococcus aureus (MRSA), vancomycin-
resistant enterococcus (VRE), and Pseudomonas, are 
frequently detected as causative microorganisms.
Many patients with cholangitis with a microbial-
positive blood culture have the same species of bacteria 
in blood as those isolated from bile cultures (level 3b),12 
and the positive rate increases with the co-existence of 
acute cholangitis due to biliary obstruction (level 2b).1 
The blood culture-positive rates in acute cholangitis 
have been reported to vary from 21% to 71% (level 
5).9–11,15 Patients with bacteremia are frequently resis-
tant to treatment regimens (level 4),16 and bacteremia 
is correlated with the duration of hospitalization, the 
incidence of postoperative renal failure, and the mortal-
ity rate (level 2b).1 These fi ndings underscore the im-
portance of antisepsis therapy, as outlined in the 
Surviving Sepsis Campaign guidelines of the Society of 
Critical Care Medicine.17
There has been no good-quality evidence to support 
the importance of blood and bile culture in patients with 
Table 1. Bacterial culture positive rates in bile (%) in various biliary diseases
     Choledo-
  Non-biliary Chole- Acute cholithiasis Hepatolithiasis
 Bile disease lithiasis cholecystitis (+cholangitis) (+cholangitis)
Chang (2002)4 Gallbladder  17.0 47.0 63.0 70.0
 Bile duct
Csendes (1996)5,6 Gallbladder 0 22.2 46.1
 Bile duct  23.9 29.0 58.2 93.9
Csendes (1994)39 Gallbladder 0 32.0 41.0 58.0
Maluenda (1989)2 Bile duct    76.0 89.0
 Gallbladder 0  43.0 (Chronic; 30)
Csendes (1975)40 Gallbladder wall   47.0 (Chronic; 33)
Kune (1974)41 Gallbladder 0 13.0 54.0 59.0
 Bile duct
Table 2. Bacterial species identifi ed in bile of patients with 
acute cholangitis2,4–8
Bacteria Positive rate in bile (%)
Aerobes
 Escherichia coli 31–44
 Klebsiella 8.5–20
 Enterobacter 5–9.1
 Proteus 1–4.8
 Salmonella typhi 0.8–2.6
 Salmonella paratyphi 0.8–2.3
 Citrobacter 1.6–4.5
 Pseudomonas 0.5–7
 Streptococcus spp. 2–10
 Enterococcus faecalis 2.6–10
Anaerobes
 Clostridium 3–12.7
 Bacteroides 0.5–8
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<Panelists from abroad>
YES
NO
<Japanese panelists> 
NO
YES
Fig. 1. Responses to the question: “Should bile culture be 
performed in all patients with acute cholangitis?” Yes, 26 
(74%); no, 9 (26%) in 35 overseas panelists, and yes, 17 (89%); 
no, 2 (11%) in 19 Japanese panelists
<Panelists from abroad> <Japanese panelists> 
YES
NO
YES
NO
Fig. 2. Responses to the question: “Should blood culture be 
performed in all patients with acute cholangitis?” Yes, 20 
(77%); no, 6 (23%) in 26 overseas panelists, and yes, 12 (46%); 
no, 14 (54%) in 26 Japanese panelists
acute cholangitis. At the Tokyo Consensus Meeting, we 
reached a consensus on the importance of bile culture 
for patients with acute cholangitis (Fig. 1). By contrast, 
there was a signifi cant discrepancy between Japanese 
and overseas panelists in regard to the importance 
placed on blood culture for all patients; while more than 
half of the overseas panelists agreed on the necessity for 
blood culture, most of the Japanese panelists disagreed 
(Fig. 2). Representative reasons for the disagreement 
were that, usually, blood cultures did not provide any 
information beyond that provided by bile cultures, and 
that postoperative acute cholangitis in patients with a 
choledocho-jejuno anastomosis did not need intensive 
bacteriological studies. It is, however, rational to rule 
out bacteremia, when possible, in patients with severe 
cholangitis, as this would affect the duration of antimi-
crobial therapy.
Q2. How are antimicrobial agents used for patients 
with acute cholangitis?
•  Antimicrobial agents should be administered to 
all patients diagnosed as having acute cholangitis 
(recommendation A); the Antimicrobial agents 
should be administered as soon as the diagnosis 
of acute cholangitis is suspected or established.
•  For patients with moderate (grade II) or severe 
(grade III) acute cholangitis, antimicrobial 
agents should be administered for a minimum 
duration of 5–7 days. More prolonged therapy 
could be required, depending on the presence 
of bacteremia and the patient’s clinical response, 
judged by fever, white blood cell count, and C-
reactive protein, when available (recommenda-
tion A).
•  For patients with mild (grade I) acute cholangi-
tis, the duration of antimicrobial therapy could 
be shorter (2 or 3 days) (recommendation A).
An important and fruitful discussion was held regarding 
the duration of antimicrobial therapy for patients 
with acute cholangitis (see “Discussion”). In summary, 
patients with moderate (grade II) or severe (grade III) 
acute cholangitis should receive a minimum duration 
of therapy of 5–7 days, and then, based on the anatomy 
of the disease and the presence of bacteremia, and 
their clinical responses, patients may need more pro-
longed therapy. However, for the large group of pa-
tients with mild (grade I) cholangitis, 2 or 3 days of 
antimicrobial therapy is likely to be suffi cient. Need-
lessly prolonged antimicrobial therapy risks adverse 
reactions to the antimicrobials, and intensifi es pressure 
for the development and acquisition of resistant 
bacteria.
Q3. What  are the most important factors for 
consideration in antimicrobial drug selection?
(1)  Antimicrobial activity against causative 
bacteria
(2) Severity of cholangitis
(3)  Presence/absence of renal and hepatic disease
(4)  Past history of antimicrobial administration to 
the patient
(5)  Local susceptibility patterns (antibiogram) of 
the suspected causative organisms
(6)  Biliary penetration of the antimicrobial 
agents.
The dose of the antimicrobial agent should be reduced 
for patients with reduced renal function. Because most 
cephalosporin, penicillin, aminoglycoside, and carbap-
enem antimicrobial drugs are excreted by the kidneys, 
the dose is reduced for patients with nephropathy and 
decreased renal function. The Sanford guide to antimi-
crobial therapy, 200318 and Goodman and Gilman’s the 
pharmacological basis of therapeutics19 recommend that 
renal function be estimated by the following formula:
Creatinine clearance predicted from serum creatinine 
(×0.85 for females) = (140 − age)(optimum body 
weight (kg)) / (72 × serum creatinine mg/dl)
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where male optimum body weight is 50.0 kg + 0.91 kg/
cm (150 cm and taller) and female optimum body weight 
is 45.5 kg + 0.91 kg/cm (150 cm and taller).
Drug dosage adjustment should be done in pa-
tients with decreased renal function. The Sanford 
guide to antimicrobial therapy and Goodman and 
Gilman’s the pharmacological basis of therapeu-
tics should be consulted (recommendation A).
Drug dosage adjustment for ceftriaxone is not necessary 
in patients with renal failure. But dose adjustment of 
ceftriaxone is indicated for patients with severe hepatic 
impairment.18 In addition, when biliary obstruction that 
blocks the enterohepatic circulation of bile is present, 
the administration of third- and fourth-generation ceph-
alosporins may replace the intestinal fl ora and disturb 
vitamin K absorption, in turn risking coagulopathic 
hemorrhage. This phenomenon, leading to bleeding 
tendency, can be enhanced in patients with comorbid 
liver diseases or liver failure due to severe acute chol-
angitis. Intravenous administration of vitamin K may be 
indicated in these situations.
Q4. Should biliary penetration be considered 
important in the selection of therapeutic antimicrobials 
in acute cholangitis?
Biliary penetration should be considered in the 
selection of antimicrobial agents in acute cholan-
gitis (recommendation A).
It has been debated whether antimicrobials with good 
biliary penetration should be recommended for acute 
cholangitis. Indeed, there was a common belief, particu-
larly in Japan, that antimicrobial agents with excellent 
biliary penetration are more effective for the treatment 
of acute cholangitis. However, there are no clinical or 
experimental data to strongly support the recommenda-
tion of antimicrobials with excellent biliary penetration 
for these patients. In fact, in most patients with acute 
cholangitis, biliary obstruction is usually present, and 
antimicrobial drugs may not be detected in bile even if 
they demonstrate excellent biliary excretion in normal 
conditions (level 3b–4).20–27
Nevertheless, at the Consensus Meeting, we reached 
a consensus that the importance of biliary penetration 
should be emphasized for the empirical selection of 
antimicrobial agents (Fig. 3). For details, see “Discussion 
at the Tokyo International Consensus Meeting.” In 
Table 3, we list antimicrobial agents with good biliary 
penetration.
Q5. What are the results of clinical trials regarding 
antimicrobial therapy in acute cholangitis?
The combination of ampicillin and an aminoglycoside 
was regarded as a standard regimen for cholangitis in 
the 1980s (level 4–5),28,29 and most randomized con-
trolled trials (RCTs) have concluded that recently 
developed antimicrobial drugs had effectiveness and 
usefulness equivalent to that of ampicillin and amino-
glycosides (Table 4) (level 2b).30–35 Therefore, according 
<Panelists from abroad>
YES
NO
YES
NO
 <Audience> <Japanese panelists>
YES
NO Fig. 3. Responses the question: “Should the biliary penetration of antimicrobial 
agents be considered important in the in 
selection in moderate (grade II) or severe 
(grade III) acute cholangitis?” Yes, 24 
(89%); no, 3 (11%) in 27 overseas panel-
ists; yes, 18 (67%); no, 9 (33%) in 27 Japa-
nese panelists; and yes, 55 (86%); no, 9 
(14%) in 64 audience members
Table 3. Intravenous antimicrobial drugs with good biliary penetration (level 4)18
Penicillins Piperacillin, aspoxicillin, piperacillin/tazobactam, ampicillin
Cephalosporins
 1st Generation Cefazoline
 2nd Generation Cefmetazole, cefotiam, fl omoxef
 3rd, 4th Generation Cefoperazone/sulbactam,20 ceftriaxone,42 cefozopran, cefpirome, ceftazidime, cefoperazone
Fluoroquinolones Ciprofl oxacin,20 Pazufl oxacin
Monobactams Aztreonam21
Lincosamides Clindamycin38
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to the clinical trials available so far, piperacillin, ampi-
cillin and an aminoglycoside, and several cephalospo-
rins, are recommended for the treatment of acute 
cholangitis.
However, at present antimicrobial agents widely used 
for acute cholangitis, including penicillin/β-lactamase 
inhibitors, carbapenems, and the third- and fourth- 
generation cephalosporins, have not been tested in 
these RCTs. In this regard, we recommend the alterna-
tive regimens for antimicrobial agents stated in the To-
kyo Guidelines. The recommendations were reached in 
a consensus-based manner, as follows.
Q6. What are the current recommendations for 
antimicrobial therapy in acute cholangitis?
•  Antimicrobial drugs should be selected accord-
ing to the severity assessment (recommendation 
A).
•  Empirically administered antimicrobial agents 
should be changed for more appropriate agents 
according to the identifi ed causative microor-
ganisms and their sensitivity to antimicrobials 
(recommendation A).
In the Infectious Diseases Society of America (IDSA) 
guidelines for intraabdominal infections, the selection 
of antimicrobial agents is based on the severity of 
the infection.36 In the Tokyo Guidelines, the selection 
of antimicrobial agents is based on the severity of 
acute cholangitis. However, it should be emphasized 
that there is little high-level evidence that supports this 
notion.
It was widely accepted at the Consensus Meeting that 
empirically administered antimicrobial agents should 
be changed for more appropriate agents according to 
the identifi ed causative microorganisms and their sensi-
tivity to antimicrobials (Fig. 4).
In any guidelines, recommended doses of antimicro-
bials, ideally based on body weight, should also be pro-
vided. However, the dose administered can vary in each 
country, depending on medical practices and legal regu-
lations. For instance, it was known and discussed at the 
Consensus Meeting that the legally approved doses of 
antimicrobials in Japan are different from those used in 
the United States and Europe. Therefore, recommend-
ed doses of antimicrobial agents are not provided in the 
Tokyo Guidelines, and doses should be determined ac-
cording to local rules and regulations. Similarly, the cost 
of the agents, which should also be discussed, varies in 
Table 4. Comparative tests clinical of antimicrobial drugs in acute cholangitis
    Statistical
Authors (Year) Subjects Administered antimicrobials Clinical cure rate signifi cance
Muller (1987)30 Cholangitis Ampicillin+ tobramycin  85% (17/20)
  Piperacillin  60% (9/15) NS
  Cefoperazone  56% (10/18) P < 0.05
Gerecht (1989)31 Cholangitis Mezocillin  83% (20/24) P < 0.01
  Ampicillin + gentamicin  41% (9/22)
Thompson (1990)32 Cholangitis Piperacillin  70% NS
  Ampicillin + tobramycin  69%
Chacon (1990)33 Cholangitis + cholecystitis Pefl oxacin  98% (49/50) NS
   Ampicillin + gentamicin  95.7% (45/47)
Thompson (1993)34 Cholangitis + cholecystitis Cefepime  97.5% (78/80) NS
   Mezlocillin + gentamicin 100% (40/40)
Sung (1995)35 Cholangitis Ciprofl oxacin  85% (39/46) NS
  Ceftazidime + ampicillin + metronidazole  77% (34/44)
<Japanese panelists> <Audience > <Panelists from abroad>
YES
NO
YES YES
NO
Fig. 4. Reponses to the question: “Should 
empirically administered antimicrobial 
drugs be changed for more appropriate 
agents, according to the identifi ed caus-
ative microorganisms and their sensitivity 
to antimicrobials?” Yes, 30 (100%) in 30 
Japanese panelists; yes, 21 (87%); no, 3 
(13%) in 24 panelists from abroad; and 
yes, 61 (92%); no, 5 (8%) in 66 audience 
members
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organisms. Of note, the ratio of penicillin to tazobactam 
is different in Japan (4 : 1) from that in the United States 
(8 : 1).
Q7. Is there any difference between Japan and the 
United States in the use of antimicrobial agents for 
acute cholangitis?
On the basis of pharmacokinetics and pharmacodynam-
ics, there is a signifi cant difference between the United 
States and Japan in antimicrobial dosing regimens. For 
details, see “Discussion”, for discussions held at the 
Tokyo International Consensus Meeting.
As a consequences of the inappropriate dosing 
regimens in Japan, inadequate clinical responses may 
be seen in Japanese patients. Moreover, the overuse of 
broad spectrum agents such as carbapenems has been 
another problem in Japan. Unpublished data from a 
major global pharmaceutical company indicate that 
Japan consumes half of the carbapenems produced 
worldwide. This could be evidence of the overuse of 
carbapenems in Japan.
Q8. How should antimicrobial drugs be 
administered for acute cholangitis associated 
with biliary obstruction?
The presence of biliary obstruction may signifi -
cantly infl uence the biliary penetration of the an-
timicrobial, as well as acting as a persistent source 
of infection. Therefore, patients with acute cholan-
gitis, especially those with severe (grade III) dis-
ease, should have immediate biliary drainage 
along with appropriate antimicrobial therapy (rec-
ommendation A).
When biliary obstruction is present, even an antimicro-
bial drug with excellent biliary excretion may not enter 
the bile tract (level 3b–4).20–27 The active transfer of an-
timicrobial drugs into bile is not restored early after the 
biliary obstruction has been relieved (level 4).25,38 There-
fore, immediate biliary drainage, as well as the admin-
Table 5. Antibacterials for grade I acute cholangitis
First-generation cephalosporins Cefazoline
Second-generation Cefmetazole, cefotiam, 
 cephalosporins  oxacephem, fl omoxef
Penicillin/β-lactamase inhibitor Ampicillin/sulbactam
Table 6. Antibacterials for moderate (grade II) and severe (grade III) acute cholangitis
First options
Wide spectrum penicillin/β-lactamase inhibitor (as single agents) Ampicillin/sulbactam, piperacillin/tazobactam
Third- and fourth-generation cephalosporins Cefoperazone/sulbactam, ceftriaxone, ceftazidime, 
cefepime, cefozopran
Monobactams Aztreonam
One of above + metronidazole (to cover anaerobes)
Second options
Fluoroquinolones Ciprofl oxacin, levofl oxacin, pazufl oxacin
One of above + metronidazole (to cover anaerobes)
Carbapenems  Meropenem, imipenem/cilastatin, doripenem
different countries and was not addressed in the Tokyo 
Guidelines.
Antibacterials selected for the three grades of 
acute cholangitis
Mild (grade I) acute cholangitis
Mild (grade I) cases of the disease are often caused by 
a single intestinal organism, such as E. coli, and there-
fore monotherapy with one of the following antimicro-
bial drugs should be chosen. Because intestinal organisms 
producing β-lactamase, which are resistant to penicillins 
and cefazoline, are likely to be detected, the use of a 
penicillin/β-lactamase inhibitor, such as piperacillin/
tazobactam,37 or ampicillin/sulbactam is recommended 
(see Table 5).
Moderate (grade II) and severe (grade III) acute 
cholangitis (Table 6)
Patients with moderate (grade II) and severe (grade III) 
disease are often infected with multiple and/or resistant 
organisms (level 2b–3b).3,12,14 Thus, third- and fourth-
generation cephalosporins, with a wide antimicrobial 
spectrum, as well as broadspectrum penicillin/β-lac-
tamase inhibitors, are recommended as the drug of fi rst 
choice. Depending on the local susceptibility patterns 
(antibiogram), if the drug of fi rst choice is ineffective, 
fl uoroquinolones and carbapenems can be used.
It should be emphasized that the inappropriate use 
or overuse of third- and fourth-generation cephalospo-
rins and carbapenems would likely result in the emer-
gence of resistant bacteria. For instance, it has been 
reported that some E. coli strains acquire resistance to 
ampicillin/sulbactam.
Piperacillin/tazobactam is strongly recommended 
when Pseudomonas spp. are considered as the causative 
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istration of antimicrobials, is crucial in view of controlling 
the source of infection.
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Discussion at the Tokyo International 
Consensus Meeting
The issue of the Signifi cant difference between 
the United States and Japan in antimicrobial 
dosing regimens
Harumi Gomi (Japan): In the United States, ampicillin/
sulbactam — one of the most commonly used agents for 
intraabdominal infections — the regular dosage for 
adult patients with normal renal function is 3 g intrave-
nously every 6 hours, and the total dosage is 12 g per 
day. On the other hand, in Japan, the legally approved 
dosage is 3 g intravenously twice a day, meaning the 
maximum daily dose is 6 g. Another example is piper-
acillin/tazobactam. The FDA-approved dosage is 3.37–
4.5 g intravenously every 6–8 h, meaning 13.5–17.5 g per 
day. On the other hand, in Japan, the regular dose or 
legally approved dose is 2.5 g intravenously twice a day, 
meaning 5 g per day is the maximum. [In regard 
to] aminoglycosides: [for] gentamicin; in the United 
States, the regular dosage is 1–1.7 mg per kg every 8 h, 
or 4.5–5.0 mg per kg every 24 h as a once-daily dosage. 
Therefore for adult patients with a body weight of up 
to 50 kg, the daily dose is 225–250 mg. But again, in 
Japan, the maximum dose is 80–100 mg per day, regard-
less of body weight. So there is a signifi cant issue and 
difference.
How long should antimicrobial agents be given for 
patients with acute cholangitis?
Joseph S. Solomkin (USA): The other point I will make, 
just to relay our experience in North America, is that 
there is increasing emphasis on shortened duration of 
therapy, and typically now the standard recommenda-
tion for treatment would be approximately 7–10 days 
until the patient is afebrile, has resolved their infection 
clinically, and is taking oral intake. There are a lot of 
people who think that that is too long; that in fact 5 days 
may be the optimal therapy, so I think that is another 
very important area to look at, because certainly the 
longer patients are on these very broadspectrum agents, 
the greater the potential harm in terms of superinfec-
tion and toxicity.
Henry A. Pitt (USA): That was my point as well. I 
give a short course if there is no bacteremia, and then 
try to stop quickly, but I give a real course of 7–10 days 
if there is bacteremia.
Joseph Solomkin: Has anybody  .  .  .  I would just like 
to ask one question since I think you people have more 
experience than I do with this; if a patient has an epi-
sode of cholangitis, is short-course treatment — say 5 
days — is there a risk they will develop liver abscesses? 
So when we are talking about the duration of therapy, 
should that be a factor in it?
Henry Pitt: I think it depends a lot on the exact 
clinical situation. I mean, we see cholangitis most 
often now in patients who have indwelling stents, who 
come in and they get their stent changed, and then the 
bile is fl owing again and the cholangitis goes away 
quickly, and they either have had a liver abscess or not 
when they come in, and you fi gure that out, if they do 
not respond to the usual therapy and/or they have blood 
cultures.
Serafi n C. Hilvano (Philippines): I would also agree 
that we set a minimum number of days for the 
therapy.
Thomas R. Gadacz (USA): There are a lot of specifi cs 
that have been brought up, such as liver abscess, 
you would treat a patient for a long period of time. 
Patients where the acute cholangitis may be simply be 
due to a plugged-up stent which gets changed very 
quickly, in which case short-term therapy would be 
probably very appropriate. So I think that the absolute 
determination here is not one that that is trying to be 
a solution, but really a guideline and that is stated 
in the question, “should be.” The specifi c situation 
then could be altered depending upon what the exact 
condition is.
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Should biliary penetration be considered important 
in the selection of therapeutic antimicrobials in 
acute cholangitis?
Henry Pitt: The fi rst point has to do with biliary penetra-
tion. I think that there is a spectrum of disease, and ini-
tially before drainage the biliary penetration probably 
makes no difference, and having good blood levels is 
very important. But I think after drainage, I imagine, 
although there are no good data, that their biliary pen-
etration gradually goes up and that there may be some 
advantage 3 or 4 days into an illness when someone is 
very sick, I do not know.
Chen-Guo Ker (Taiwan): In cases of obstruction, the 
penetration of antibiotics was very low, in the studies 
more than 10 years ago. So it is better to give the drain-
age in the fi rst acute phase. But during the acute phase, 
we have to keep the antibiotics for prevention of the 
systemic bacteremia; so that you do not mention. It is 
not necessary to care about the penetration into the bile. 
But another thing which is very important; antibiotic 
penetration into the bile, this should be combined with 
the ligand-specifi c protein. So in cases of patient with 
low albuminemia, last penetrated into the bile must be 
very low. So we have to care about the timing of the 
giving of antibiotics and what kind of antibiotics we use. 
It is my opinion. Thank you.
(Voting was done)
Joseph Solomkin: You know, I think the numbers, 
particularly from our Japanese hosts, are strong enough 
so that in the guidelines we should say or make the 
statement that it is the opinion of the Japanese that bili-
ary penetration is important.
Steven M. Strasberg (USA): But is the other point not 
given that what we are here to do is that there is not 
good evidence from the literature of the importance of 
this factor?
Atsushi Tanaka (Japan): Well, as I have said, there is 
very little evidence suggesting the importance of this.
Steven Strasberg: Well, that is what I mean; there is 
very little evidence, so it is really a point that we cannot 
make a rational decision about it, so it is about as au-
thoritarian as you can get.
Joseph Solomkin: That is why it was brought up for 
discussion, but I think here that Dr. Tanaka made the 
point very clearly that that was the case; that the supe-
riority just is not there, it has not been demonstrated. 
Conversely, if you have a group of practitioners who 
strongly believe something that is not critical to the 
health of the patient, I would be more concerned of 
risking their not using the guidelines at all. That is a very 
big question.
Yoshifumi Kawarada (Japan): Sir. I have to ask Dr. 
Gomi, what do you think about the biliary penetration 
by antibiotics in acute cholecystitis?
Harumi Gomi: Well, since all my training was done 
in the United States, I am more towards the United 
States position. This means that I do not consider the 
penetration of the biliary tract.
Yoshifumi Kawarada: Yes, I had the same opinion. I 
had a bias. I was educated in the United States, always 
being against the penetration, it is not so important; but 
for Japanese people, 71% say “Yes.”
Steven Strasberg: I fi nd it very diffi cult to understand 
how we can publish a guideline that says anything that 
is not a refl ection of the best available evidence; and 
think that whether someone is going to follow a guide-
line or not is a second degree of relevance, or a second 
degree of what we should be considering. I do not know 
this literature, but if the literature says that drugs that 
do penetrate the biliary epithelium do not do any better 
than drugs that do not penetrate the biliary epithelium, 
then just as you have said before, the evidence is that it 
is a factor of no importance or minor importance, and 
I think the guidelines should say that.
Joseph Solomkin: The reservation — I appreciate you 
saying that — the reservation I have is that these are 
consensus guidelines, so that they are guidelines that 
basically  .  .  .  these guidelines, as far as I am concerned, 
or were I to write them would say, “The evidence is such 
and such; at the consensus meeting, nonetheless, the 
panelists believe because of current common practice, 
that such and such is okay.” I think you have to do both 
things; state the facts and then I do not think you can 
discredit the consensus.
Henry Pitt: Part of the problem is that we have no 
good evidence. The paper that is quoted as the best evi-
dence is Michael Keith-Floyd’s paper that was pub-
lished in 1974, and it was a retrospective analysis of 
whether people were treated with gentamicin or not. 
That is not good evidence either. So we have to make 
a recommendation, and then we say it is based on A-, 
B-, C-, D-, or E-level evidence, and this will be a lower-
level evidence recommendation.
